[
  {
    "element_id": "elem_001_0001",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      36.63035980224609,
      717.5759326171875,
      546.9064453125,
      736.25291015625
    ],
    "confidence": 0.985614001750946,
    "reading_order": 1,
    "content": "T06450,USA. 3GlobalMedicalAffairs,Sanofi Pasteur,1DiscoveryDrive,Swiftwater,PA18370,USA. email:Arun.Arunachalam@sanofi.com\n\u2709\nAnalyticalSciences,R&DSano Pasteur,1DiscoveryDrive,Swiftwater,PA18370,USA. RegulatoryAffairs,ProteinSciences,aSano Company,1000ResearchParkway,Meride"
  },
  {
    "element_id": "elem_001_0002",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      34.28806915283203,
      608.8109326171875,
      287.18578125,
      701.300390625
    ],
    "confidence": 0.9943521022796631,
    "reading_order": 2,
    "content": "protein, neuraminidase (NA), cleaves sialic acid and releases\nshowntoprotectthehostfrominfection10,11.Anotherviralsurface\neffectively prevent viral entry into target cells and have been\nlateendosomalmembrane.NeutralisingantibodiesthatblockHA\nhostcellentryandmediatesthefusionoftheviralenvelopetothe\ntheviralsurface,HAbindstosialicacidontargetcellstofacilitate\nthus a key vaccine target. Expressed as trimeric glycoproteins on\na protective immune response against the influenza virus, and\nHaemagglutinin(HA)istheprimaryantigenintheinductionof"
  },
  {
    "element_id": "elem_001_0003",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      35.3551821899414,
      507.0873779296875,
      282.6301904296875,
      608.325380859375
    ],
    "confidence": 0.992618978023529,
    "reading_order": 3,
    "content": "stockpiled as government initiatives for emergency use i\nandH1N1in2009).Vaccinesagainstsuchstrainsarepreparedan\na global pandemic (H1N1 in 1918; H2N2 in 1957; H3N2 in 1968\ninfluenzaAvirusstrainshaveemergedinthisway,eachleadingt\nanimal reservoirs to humans9. In the past century, four nove\nalsogiverisetohighlypathogenicvirusesthroughcross-overfro\nincludedinseasonalinfluenzavaccines8.InfluenzaAsubtypesca\nB/Yamagata and B/Victoria circulate routinely in humans and ar\nInfluenzaAsubtypesH1N1andH3N2,andinfluenzaBlineage"
  },
  {
    "element_id": "elem_001_0004",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      35.05644470214843,
      397.727841796875,
      284.17403320312496,
      509.0659716796875
    ],
    "confidence": 0.9939171671867371,
    "reading_order": 4,
    "content": "pandemics,is thusaglobal priority.\nseasonal influenza epidemics, as well as preparedness for future\ncarries substantial social and economic cost6,7. Prevention of\nrecogniseddiseaseburden4,5.Overall,suchahighdiseaseburden\ncomplications of influenza infection constitute a further under-\nyoungchildrenandadultsaged65andolder1,2,4.Extra-pulmonary\n2019\u20132020 season. These numbers are significantly higher in\naccount for 52.7 hospitalisations per 100,000 people during the\nsevereillnessworldwide1\u20133.IntheUSA,influenzawasthoughtto\nyear due to respiratory diseases alone and 3\u20135 million cases of\nSeasonal influenza is responsible for 290,000\u2013650,000 deaths per"
  },
  {
    "element_id": "elem_001_0005",
    "page_num": 1,
    "element_type": "title",
    "bbox": [
      34.747816772460936,
      387.051240234375,
      98.867109375,
      398.17248046875
    ],
    "confidence": 0.9984456896781921,
    "reading_order": 5,
    "content": "INTRODUCTION"
  },
  {
    "element_id": "elem_001_0006",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      301.73644775390625,
      647.5705224609375,
      549.0770800781249,
      699.584853515625
    ],
    "confidence": 0.9940469264984131,
    "reading_order": 6,
    "content": "distribution,takeseighttoninemonthseachyear.Agile,reliabl\ninfluenza strains to vaccine manufacture and release fo\nagainst-time21. The production process, from the selection o\ntional, mostly egg-based platforms, is arduous and a race\nThe annual production of influenza vaccine through conven"
  },
  {
    "element_id": "elem_001_0007",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      302.024091796875,
      535.9396728515625,
      551.2891113281249,
      649.046162109375
    ],
    "confidence": 0.9889411330223083,
    "reading_order": 7,
    "content": "argetsfor developmentof universalinfluenzavaccines19,20.\nonserved regions on the HA head and stem present attractive\ndeal against constantly evolving influenza viruses. As such, the\nild-typestrainsandcross-protectiontorelatedstrainswouldbe\ntem18. Vaccines that can induce immunity specific to circulating\nntibodies specific to conserved regions on the HA head and\ny vaccination or natural infection and is primarily due to\nrotectioncanoccurthroughtheprimingoftheimmunesystem\ngainst the predominant circulating virus strains16,17. Such cross-\nnfluenza illness, even when there is an antigenic mismatch\nInfluenza vaccines can afford significant protection against"
  },
  {
    "element_id": "elem_001_0008",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      301.03916748046873,
      436.947626953125,
      550.0652343749999,
      542.3653564453125
    ],
    "confidence": 0.9664266109466553,
    "reading_order": 8,
    "content": "resultingvaccinetargetsismadebyindividualregulatorybodies.\nSurveillanceandResponseSystem(GISRS)15.The finaldecisionon\nJapan, China and Australia as part of the WHO Global Influenza\n(includingtheCentersforDiseaseControlandPrevention[CDC]),\n(WHO) collaborating centres at six locations in the UK, USA\non surveillance data collected by World Health Organization\nthe vaccine. Identification of the target influenza strains is based\nmostlikelytospreadduringtheupcomingseason,forinclusionin\nthe identification of the influenza strains and their like strains,\nThepreparationoftheannual in uenzavaccine rstly requires"
  },
  {
    "element_id": "elem_001_0009",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      303.16693359375,
      387.15169921874997,
      550.47779296875,
      436.31789062499996
    ],
    "confidence": 0.9860973358154297,
    "reading_order": 9,
    "content": "fl 13,14\nnnualinfluenzavaccinationmayhelptobroadenprotectionand\nequired for effective vaccine performance12, its inclusion in\nmportant vaccine target. Although the presence of NA is not\nudding virus from the infected cells, thus serving as another"
  },
  {
    "element_id": "elem_001_0010",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      51.047336425781246,
      339.83958251953123,
      309.52997314453125,
      349.8869311523437
    ],
    "confidence": 0.7284221053123474,
    "reading_order": 10,
    "content": "(2021)6:144; https://doi.org/10.1038/s41541-021-00403-"
  },
  {
    "element_id": "elem_001_0011",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      41.327347412109376,
      178.87327514648436,
      540.682998046875,
      339.35302001953124
    ],
    "confidence": 0.957181453704834,
    "reading_order": 11,
    "content": "suchasforCOVID-19.\nrecombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltargets,\nreactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityofthe\neggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadverse\nantibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenceof\ncertainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotective\nstructuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexpose\nrecombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary\ntoconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristicof\nstudiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompared\nsystemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbeen\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration\nTheinfluenzavaccine fieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and flexibilityofmanufacturing,andto"
  },
  {
    "element_id": "elem_001_0012",
    "page_num": 1,
    "element_type": "text",
    "bbox": [
      33.21237854003906,
      151.59834228515624,
      273.558427734375,
      162.66554077148436
    ],
    "confidence": 0.9735447764396667,
    "reading_order": 12,
    "content": "ArunB.Arunachalam ,PennyPost and Deborah Rudin"
  },
  {
    "element_id": "elem_001_0013",
    "page_num": 1,
    "element_type": "title",
    "bbox": [
      23.642270507812498,
      98.54785766601562,
      536.6185400390625,
      143.76539794921874
    ],
    "confidence": 0.9803076386451721,
    "reading_order": 13,
    "content": "vaccine that in uence vaccine performance\nfl\nUnique features of a recombinant haemagglutinin in uenza"
  },
  {
    "element_id": "elem_002_0014",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      45.509842529296876,
      694.815380859375,
      293.0445703125,
      735.7447705078125
    ],
    "confidence": 0.985846221446991,
    "reading_order": 1,
    "content": "irculating strains27. Differences in HA glycosylation between th\nhe selected vaccine strain appeared to be well matched t\n3N2thanforotherstrainssince2009,evenduringseasonswhe\nLower vaccine effectiveness estimates have been observed fo"
  },
  {
    "element_id": "elem_002_0015",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      46.45809448242187,
      472.4979345703125,
      292.37675537109374,
      695.71265625
    ],
    "confidence": 0.9943491816520691,
    "reading_order": 2,
    "content": "therinfluenzaseasons26,27.\nontributed to low vaccine effectiveness estimates for H3N2 i\ntrain during vaccine manufacturing are thought to hav\nntigenicmutationsintroducedbyegg-adaptationofthevaccin\nhese three mutations during vaccine production25. Othe\nbserved for H3N2 in the 2012\u20132013 season was attributed t\n156Q,G186V,andS219Y25.Thelowvaccineeffectiveness(41%\nnd several other wild-type influenza viruses in three positions\nanufacturing differed from the WHO-recommended prototyp\ngg-adapted A/Victoria/361/2011 (H3N2) virus used for vaccin\northernhemisphereinfluenzavaccinationcampaign,HAfroma\niallyoverthecirculatingwild-typevirus24.Duringthe2012\u2013201\neceptorbindingsitethatboundtovaccine-derivedHApreferen\nt position 226 which in turn induced antibodies specific t\nutation resulting in the substitution of glutamine with arginin\ndapted A/California/07/2009 (H1N1) vaccine strain acquired\nesultant vaccine24\u201326. Raymond et al.24 showed that an egg\nutations in HA peptides may reduce the effectiveness of th\nammalianhostcellsduringvaccinemanufacture.Suchadaptiv\ndaptivemutationsastheygrowinembryonatedchickeneggo\nor thecandidate vaccine virus or working virus seeds to acquir\nknownriskoftraditionalsplitorsubunitvaccinesisthepotentia"
  },
  {
    "element_id": "elem_002_0016",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      311.72923828125,
      685.0436132812499,
      559.7225244140625,
      736.803984375
    ],
    "confidence": 0.992691695690155,
    "reading_order": 3,
    "content": "e non-inferior in terms of vaccine efficacy against respiratory\nuadrivalent VLP (QVLP) at 30\u00b5g dose per strain was found to\nmmunogenic in humans34\u201337. A plant-derived recombinant\nn virus-like particles (VLPs) have been shown to be safe and\nVaccinescontainingplant-derivedrHAeitherinsolubleformor"
  },
  {
    "element_id": "elem_002_0017",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      311.50799560546875,
      413.94282714843746,
      559.34419921875,
      687.2477783203125
    ],
    "confidence": 0.9731311202049255,
    "reading_order": 4,
    "content": ". coli-expressed influenza vaccines.\narge scale manufacturing and eventual commercialisation o\nnimal models31. These inherent complications have prevented\nreater quantity needed to generate protective immunity i\nmmunogenic than egg-derived antigens, with around a 10-fold\nonformation31. The resulting processed proteins are less\ning to attain desired purity and to fold to their nativ\nndergo glycosylation33. They therefore need extensive proces\nolding, contain impurities (e.g., host-cell proteins), and do no\nowever, E. coli-expressed rHA proteins can be subject to mis\nill likely shorten the entire vaccine manufacturing process32\nedium-scalepharmaceuticalproductionfacility31.Thisapproac\nould yield up to half a billion doses of vaccine per month in\numberofbioreactors31.Theauthorsprojectedthatthestrateg\nields of rHA (200mg/L of purified HA protein) using a minima\n. coli expression system has been shown to generate a hig\nesponses in healthy adults with favourable tolerability30. Th\naccine developed using this E. coli platform elicited immun\nodels29.InPhase1clinicalevaluation,aprototypicquadrivalen\nlicited strong and protective antibody responses in mous\nalmonella typhimurium flagellin type 229. The resultant vaccine\nrotein genetically fused with the Toll-like receptor 5 agonist\nnvolved expression of the globular head domain of the H\nanufactured using an Escherichia coli fermentation system\nandidate recombinant influenza vaccines to be successfull\nsed for the manufacture of rHA vaccine antigens. The firs\noth prokaryotic and eukaryotic expression systems have bee"
  },
  {
    "element_id": "elem_002_0018",
    "page_num": 2,
    "element_type": "title",
    "bbox": [
      310.1854614257812,
      403.7360009765625,
      481.83956542968747,
      414.5933056640625
    ],
    "confidence": 0.9977594614028931,
    "reading_order": 5,
    "content": "RECOMBINANTHA EXPRESSIONSYSTEMS"
  },
  {
    "element_id": "elem_002_0019",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      309.24052734375,
      263.9535864257812,
      559.002216796875,
      386.53048828125
    ],
    "confidence": 0.9972448348999023,
    "reading_order": 6,
    "content": "influenzastrain selected forvaccines is eliminated.\nofRIV4,orotherrHAvaccinesindevelopment,withthewildtyp\ninfluenzavaccineproduction.Thus,theriskofantigenicmismatc\nthe HA from the wild-type virus isolate selected for seasona\nbaculovirusorotherrecombinantexpressionsystemisidenticalt\nsuch,theprimaryamino-acidsequenceoftherHAproducedusin\nandis confirmed for fidelityat theworking virus bank level28.A\nGlobal Initiative on Sharing All Influenza Data (GISAID) databas\ncoding for HA is cloned from a reference virus published in th\ning process as it does not use \u2018live\u2019 influenza virus. Instead, DN\nacquiring egg-or cell-adaptedmutations duringthemanufactur\nRecombinant DNA technology avoids the risk of the viru"
  },
  {
    "element_id": "elem_002_0020",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      310.0489233398437,
      55.667801513671876,
      559.6372265625,
      266.99150390625
    ],
    "confidence": 0.9887930750846863,
    "reading_order": 7,
    "content": "seeds could hinderthetimelyavailability ofthevaccines.\nproduction.Nonetheless,thetimeittakestogenerateappropriate\noriginating wild-type virus before they can be used for vaccine\nbe confirmed for both genetic and antigenic match with their\nIndeed,aspercurrentregulatoryrequirements,seedvirusesmust\nlowduetothestringentqualitycontroloftheworkingseedvirus.\nadaptation ofseedvirus duringvaccine manufacturing todayare\nThe chances of introducing deleterious mutations through the\nefficiently recognised the glycosylated clade 3C.2a H3N2 virus26.\nglycosylation site induced optimal levels of antibodies that\nderived vaccines and as expected, rHA containing the new\nglycosylated clade 3C.2a H3N2 strain26. Contrary to the egg-\nbodies induced in humans, and in ferrets, poorly neutralised the\nsite was absent in the egg-adapted virus. Consequently, anti-\nthenewglycosylationsite26.However,thisparticularglycosylation\na clade 3C.2a H3N2 strain (A/Colorado/15/2014) containing\n2016\u20132017 season,theinfluenzavaccinewasupdated toinclude\na new predicted HA glycosylation site emerged26. For the\n2014\u20132015influenzaseason,aclade3C.2aH3N2strainpossessing\ncontributed to this reduced vaccine effectiveness26. During the\nvaccine strains and circulating strains are thought to have"
  },
  {
    "element_id": "elem_002_0021",
    "page_num": 2,
    "element_type": "title",
    "bbox": [
      45.65138763427734,
      443.99970703125,
      286.7105346679687,
      474.6218115234375
    ],
    "confidence": 0.9562699198722839,
    "reading_order": 8,
    "content": "UTATIONSINTHEHA PRIMARY STRUCTURE\nIRUSGROWNINEGGORCELLS DUETO ADAPTIVE\nOTENTIALANTIGENIC MISMATCH OFINFLUENZA VACCINE"
  },
  {
    "element_id": "elem_002_0022",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      43.590830383300776,
      355.07713623046874,
      295.18969482421875,
      427.521181640625
    ],
    "confidence": 0.9945554733276367,
    "reading_order": 9,
    "content": "againsta constantlyevolvingand mutating virus.\nconserved epitopes is critical for imparting cross-protection\nother viral targets, such as COVID-19, where the preservation of\nthe benefits of this manufacturing process can be extended to\nthese features help to maximise vaccine performance. Notably,\nrHAthatmakeRIV4uniquefromconventionalvaccines,andhow\nThis review focuses on the structural features of BEVS-derived"
  },
  {
    "element_id": "elem_002_0023",
    "page_num": 2,
    "element_type": "text",
    "bbox": [
      43.48760559082031,
      56.75430541992187,
      292.7242529296875,
      357.5863256835937
    ],
    "confidence": 0.975526750087738,
    "reading_order": 10,
    "content": "and various other countries.\n2013. It is now licensed in the USA, Canada, Europe, Australia\nextensiveclinicalassessment23,andwas firstapprovedbyFDAi\nfiltration for storage and formulation22. RIV4 has undergon\nusing tangential flow filtration and passed through steril\nbrane filtration. Purified rHA is suspended in relevant buffe\nextract using column chromatographies followed by Q mem\nextracted using detergent and purified from the clarified cel\npolyhedrin promotor. rHA molecules from the infected cells ar\ngenes, which are expressed under the control of a baculoviru\nrecombinant baculovirus carrying the relevant influenza H\n(BEVS)22. In brief, expresSF+ insect cells are infected wit\nin insect cells using a baculovirus expression vector syste\nproductionplatforminwhichrecombinantHA(rHA)isexpresse\nthe four strains. The production of RIV4 is based on a nove\nunadjuvantedvaccinecontaining45\u00b5gofHA/dosefromeacho\n(as for inactivated split-virion and subunit vaccines). RIV4 is a\nviralproteinsinsteadofantigensderivedfromliveinfluenzaviru\nlicensed influenza vaccine to be produced using recombinan\nFlublok\u00ae, Supemtek\u00ae [EU, Canada], Sanofi Pasteur) was the firs\ntimelines.Therecombinantquadrivalentinfluenzavaccine(RIV4\nproducenew,effectivevaccineswithinaccelerateddevelopmen\ndemonstrated the feasibility of using more efficient methods t\nin the urgent response to the COVID-19 pandemic ha\n(including mRNA, vector, and recombinant protein strategies\nadoption of alternative vaccine development approache\navian flu pandemics, when egg supply may be impacted. Th\ndelivery for upcoming epidemic seasons and during potentia\nmanufacture of influenza vaccines are needed to ensure timel\nand egg-free technologies allowing for guaranteed and faste"
  },
  {
    "element_id": "elem_003_0024",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      35.78086944580078,
      611.6582373046875,
      283.5293994140625,
      736.9537939453124
    ],
    "confidence": 0.9972500205039978,
    "reading_order": 1,
    "content": "andinpandemicsituations.VLPshavebeenproducedsuccessfull\nthetimelysupplyofinfluenzavaccineforbothseasonalepidemic\nconventionalinfluenzavaccines42,43.Thisisacriticaladvantagefo\nthan half the time (2\u20133 months) required for the manufacture o\nrHA are harvested and purified (Fig. 1). This process requires les\nthevaccineareinsertedintotheBEVS,fromwhichhighyieldso\nsequences from the wild-type strains selected for inclusion i\nnated eggs or mammalian cell-lines. Instead, HA geneti\ncandidate vaccine viruses selected for robust growth in embryo\ninsect cells does not depend on the generation of reassortan\negg-free. Like other recombinant vaccines, expression of HA i\nRIV4 is one of only two available influenza vaccines that ar"
  },
  {
    "element_id": "elem_003_0025",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      34.95655975341797,
      480.66433593749997,
      281.91181640625,
      614.27126953125
    ],
    "confidence": 0.9955484867095947,
    "reading_order": 2,
    "content": "against the vaccine antigens39,40.\ninfluenza vaccinations) can dampen the immune respons\nrepeated immunisation (for example during repeated annua\novercome this issue, AdV vector immunity developed throug\nthe use of non-human adenovirus vectors could potentiall\nthe vaccine vector and clearing the vector-infected cells. Whil\nadenovirus can hamper vaccine effectiveness by neutralisin\ndisease39\u201341.However,pre-existingoracquiredimmunityagains\nprotein, providing robust protection against the targete\nbothcell-mediatedandhumoralimmunityagainsttheexpresse\ntransgeneexpressionofrHAinthehostcells.AdVvectorsinduc\nprimarily as a replication-defective vector, for gene delivery an\nSeveral groups have explored the use of adenovirus (AdV"
  },
  {
    "element_id": "elem_003_0026",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      300.95343017578125,
      643.51037109375,
      550.1648583984374,
      735.80203125
    ],
    "confidence": 0.9959327578544617,
    "reading_order": 3,
    "content": "lower respiratory tract. However, HA from influenza subtypes H5\nfor influenza virus tropism to epithelial cells of the upper and\nthese proteases exclusively in the respiratory tract is responsible\nessential for the infectivity of influenza virus. Thus, expression of\nvirions are released from infected cells50,51. HA cleavage is\nother subtilisin family endoproteases after newly synthesised\nHA2) extracellularly by trypsin-like serine proteases, furin and\n(HA0),whichisgenerallycleavedintotwopolypeptides(HA1and\nIn uenza HA is synthesised as a single precursor polypeptide"
  },
  {
    "element_id": "elem_003_0027",
    "page_num": 3,
    "element_type": "title",
    "bbox": [
      301.2702978515625,
      621.8478369140624,
      553.5061523437499,
      642.6418798828125
    ],
    "confidence": 0.9597947597503662,
    "reading_order": 4,
    "content": "ININSECTCELLSCANINFLUENCEVACCINEIMMUNOGENICITY\nTHETERTIARY STRUCTUREOFRECOMBINANT HA PRODUCED"
  },
  {
    "element_id": "elem_003_0028",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      301.86973388671873,
      459.8144384765625,
      548.996220703125,
      603.8608447265625
    ],
    "confidence": 0.993380069732666,
    "reading_order": 5,
    "content": "vaccines with improved effectivenessand theirtimely availabilit\nthe product, should facilitate continued evolution of influenz\nthis technology, together with the molecular characterisation o\nan \u2018innovativedrug\u2019 designationfromHealthCanada49.Theuseo\nCommittee for Medicinal Products for Human Use (CHMP)48 an\ntion from FDA, a \u2018new active substance\u2019 designation from EM\nthese unique features, RIV4 received \u2018product exclusivity\u2019 protec\ncertain aspects of vaccine safety and efficacy (Fig. 2). Based o\nmaterialandthemanufacturingprocess,whichhaveanimpacto\nterms of specific structural features, the nature of the sourc\ncontainedinRIV4differs fromthatexpressedinother systemsi\nvarious groups in both pre-clinical models and humans. The rH\nInsect cell-derived rHA (RIV4) has been studied extensively b"
  },
  {
    "element_id": "elem_003_0029",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      301.45941650390625,
      297.7007739257812,
      548.54947265625,
      463.5590625
    ],
    "confidence": 0.995470404624939,
    "reading_order": 6,
    "content": "(PATH)and is notcovered here47.\npublished by the Program for Appropriate Technology in Healt\nmanufacturing has been discussed exhaustively in a repor\nespecially in a pandemic situation. This aspect of the vaccin\nto ensure adequate supply of vaccine at an affordable cost\nmanufacturing processes and technologies are critical element\nvaccines to the market. The yield and the cost of variou\nannually.Italso raises thecostand thetime ittakestobringth\na constraint for the commercial scale manufacturing of vaccine\ndisassemblyandreassemblyprocessingofpurifiedVLPs,whichi\nthese unwanted proteins from the vaccine required extensiv\nintegrated both baculovirus and Sf9 cell proteins. Elimination o\npurity of the vaccines considerably, as VLP structures als\nstructures enhanced their immunogenicity, it compromised th\nexpressedininsectcells44\u201346.AlthoughpresentingproteinsinVL\nby integrating HA, capsid protein (M1) and neuraminidase (NA"
  },
  {
    "element_id": "elem_003_0030",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      37.768785095214845,
      300.138662109375,
      283.33423828125,
      487.17531738281247
    ],
    "confidence": 0.9855679273605347,
    "reading_order": 7,
    "content": "mmuneresponses invaccinees.\no avoid potential severe adverse events caused by enhance\necontrolledandkeptataconstantlevel,forcommercialisation\ntimulatory components in a plant-derived vaccine may need t\nlant-origin lipids/glycolipids in the vaccine formulation38. Thes\nellular immune responses, potentially as a direct effect of th\nmmunity that predominantly facilitates Type 1 pro-inflammator\nttribute of plant-derived rHA is that it can stimulate innat\nhe circulating influenza viruses each season. A unique positiv\nA component of the vaccine to reflect antigenic change i\naccineproduction,whichtypicallyinvolvesupdatingatleaston\nystems34.Theunpredictable yieldcould adversely impacttimel\nenome,hasbeenamajorchallengewithplant-basedexpressio\nue to nonspecific integration of transgene(s) into the hos\nowever,inconsistencyintheexpressionlevelsoftargetproteins\niven at 15\u00b5g dose/strain in adults aged 18 to 64 years37\nnfluenza vaccine (QIV; Fluarix Quadrivalent, GlaxoSmithKline\nllness and influenza-like illness to a quadrivalent inactivate"
  },
  {
    "element_id": "elem_003_0031",
    "page_num": 3,
    "element_type": "text",
    "bbox": [
      35.03931976318359,
      263.578974609375,
      549.0259277343749,
      291.070546875
    ],
    "confidence": 0.8668315410614014,
    "reading_order": 8,
    "content": "ElsevierInc,withpermissionfromElsevier23.\nfromCox,M.M.&Hashimoto,Y(2011).Afasttrackinfluenzavirusvaccineproducedininsectcells. JInvertebrPathol 107Suppl,S31-41 \u00a9 201\nFig.1 GenerationofrHAusingthebaculovirus-insectcellexpressionsystemforthemanufactureofRIV4. BVbaculovirus.Figureadapte"
  },
  {
    "element_id": "elem_003_0032",
    "page_num": 3,
    "element_type": "figure",
    "bbox": [
      87.02554504394531,
      53.83488098144531,
      527.1608935546875,
      250.0171435546875
    ],
    "confidence": 0.9968974590301514,
    "reading_order": 9
  },
  {
    "element_id": "elem_004_0033",
    "page_num": 4,
    "element_type": "text",
    "bbox": [
      311.44201171875,
      441.94508789062496,
      555.250078125,
      737.692822265625
    ],
    "confidence": 0.9860806465148926,
    "reading_order": 1,
    "content": "onventional influenza vaccines. Together, these critical findin\ntateandtheirpotentialroleinprotection,asthesearepresenti\nmmunogenicityofreleasedHAfusionpeptidesinthepost-fusio\nxposure52,63.Nonetheless,itwouldbeofinteresttoexamineth\nequestered away from membranes in a pocket, limiting i\nhe hydrophobic fusion peptide in the N-terminus of HA2\nnfectedcells,thefusionloopiscleavedtoyieldHA1andHA2,an\nnce the virus binds to a cell or enters the acidic endosome\nn influenza virions are predominantly in the pre-fusion stat\nhatareessentialforthevirusinfectivity.HAmoleculespresente\nonformation change and the HA-mediated membrane fusio\nake the virus non-infectious by inhibiting the pH-induce\nA0andlockedHAinthepre-fusionstate.Thus,theseantibodi\nngroup1andgroup2influenzaA,blockedproteasecleavage\notencyandneutralisedadiversepanelofrepresentativevirus\nA061,62.Theseantibodiesexhibited unprecedentedbreadthan\npecific to epitopes in the fusion loop region present only i\nmmunogenorfromaphagedisplaylibrary,protectiveantibodi\nA060.Additionally,severalgroupshaveisolated,usingHA0asth\ny RIV4 may be linked to the presence of unique epitopes o\ngy, that the observed broader specificity of antibodies induce\nurther demonstrated, using surface plasmon resonance techno\nions in its pre-fusion state59. A recent study by Khurana et al.\notential dynamic state where HA undergoes structural fluctu\ntructural analysis of the antigen-antibody complex revealed\nnd transiently exposed in the pre-fusion conformation5\nntibodythatbindstoanepitopeonHAmoleculesthatarepartl\nurfaceoftheHA0rosettes.Turneretal.59 identifiedamonoclon\nind near the uncleaved fusion peptide that protrudes at th"
  },
  {
    "element_id": "elem_004_0034",
    "page_num": 4,
    "element_type": "text",
    "bbox": [
      45.67667816162109,
      644.1880078125,
      295.99305908203127,
      735.9500390625
    ],
    "confidence": 0.9976961016654968,
    "reading_order": 2,
    "content": "Amaturationandfusion58.Someoftheseantibodiesarelikelyto\nhe highly conserved HA stem region have been shown to block\nimilarly, several broadly neutralising antibodies directed against\no the post-fusion HA1\u2013HA2 heterodimer at an acidic pH57.\nresentinthepre-fusionHA0moleculewerelostuponconversion\ntrated, using monoclonal antibodies, that neutralising epitopes\neptide have been well described54. Webster et al.57 demon-\nusion states of HA and the process of exposure of the fusion\nThe conformational differences between pre-fusion and post-"
  },
  {
    "element_id": "elem_004_0035",
    "page_num": 4,
    "element_type": "text",
    "bbox": [
      47.09525207519531,
      438.47230957031246,
      293.7716015625,
      643.8263378906249
    ],
    "confidence": 0.9924742579460144,
    "reading_order": 3,
    "content": "56\nolypeptidesinSf9cellshasbeenshowntobeduetoinsufficient\nA2 molecules55. Poor processing of HA0 to HA1 and HA2\nroducedusingaBEVS,withnoproteinbandsindicativeofHA1or\nredominanceofHA0inrecombinantHAH7 subunitcomplexes,\nAGE under reducing conditions) clearly demonstrated the\nA0polypeptide(Fig.2).Apreviousbiochemicalstudy(usingSDS-\nHAincludedinRIV4isdesignedtoyieldpredominantlyasasingle\nresentpredominantlyasHA1\u2013HA2heterodimers.Bycontrast,the\naccines,theHAmoleculesderivedfromliveinfluenzavirusesare\nnfect a new host cell52,54. In inactivated (split and subunit)\nenderthemoleculefusion-competent,thusenablingthevirusto\nA1\u2013HA2 heterodimers leads to conformational changes that\nurface as trimers (HA \u2018rosettes\u2019). The conversion of HA0 to\nA1\u2013HA2 heterodimers, are expressed on the viral membrane\nFig. 2). These molecules, either uncleaved HA0 or cleaved\nemaincovalentlylinkedbyadisulfidebondtoformheterodimers\nhesestrainshighlyvirulent50,52,53.TheHA1andHA2polypeptides\nbiquitously expressed furin in the trans-Golgi network, making\nnd H7 contains multi-basic cleavage sites that are cleaved by"
  },
  {
    "element_id": "elem_004_0036",
    "page_num": 4,
    "element_type": "text",
    "bbox": [
      44.27542694091797,
      370.143369140625,
      557.3605078125,
      439.2411328125
    ],
    "confidence": 0.9902216196060181,
    "reading_order": 4,
    "content": "polypeptide.Uncleavedfusion-peptideloop(green)andsimplerglycanspreserveandexposeuniqueepitopesonrHA.\npaucimannosidic N-linked glycans74. HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a singl\ninsectcellsasasingleprecursorpolypeptide(HA0)withaminoacidsequenceidenticaltowildtypeHAsequenceandcontainsunsialylate\nandcomplexglycans74 eliminateandmaskuniqueepitopesonHArespectively. b RecombinantHAprotein(shownasmonomer)expressedi\n(orange)linkedthoughaninter-disulfide(S\u2013S)bondandcontainscomplex-typesialylatedN-linkedglycans.Cleavedfusionpeptides(green\nvector system. a HA protein (shown as monomer) extracted from influenza virus is a heterodimer comprising HA1 (turquoise) and HA\nFig.2 StructuralfeaturesofnativeHAexpressedoninfluenzavirusandrHAproducedininsectcellsusingthebaculovirusexpressio"
  },
  {
    "element_id": "elem_004_0037",
    "page_num": 4,
    "element_type": "figure",
    "bbox": [
      65.79117004394531,
      52.3698046875,
      508.940771484375,
      357.55595947265624
    ],
    "confidence": 0.9955737590789795,
    "reading_order": 5
  },
  {
    "element_id": "elem_005_0038",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      36.35095275878906,
      606.0482666015624,
      283.1363525390625,
      735.7775097656249
    ],
    "confidence": 0.9940621256828308,
    "reading_order": 1,
    "content": "A rosettes of small and uniform size.\nxtremely rare, this is unlikely to occur with RIV4 that contain\nased on study results from a mouse model70. Althoug\nnduced a Type-2 polarised immune response resulting in OR\nggregate content in the split vaccine are believed to hav\nheconventionalegg-derivedinfluenzavaccines69.Highlevelso\neduetothepresenceofmicro-aggregatesofunsplitvirionsi\nRS, induced within 2 to 24h of vaccination, was suspected t\nnfluenza split-virus vaccine68. Detailed analysis revealed tha\nere reported following immunisation with the inactivate\nasesofasyndrometermedasoculo-respiratorysyndrome(ORS\nIn Canada between 2000 and 2004, an unusual number o"
  },
  {
    "element_id": "elem_005_0039",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      35.208075256347655,
      502.059814453125,
      283.1239819335937,
      607.4204589843749
    ],
    "confidence": 0.9945138692855835,
    "reading_order": 2,
    "content": "66\nmembranefoldedinvariousshapes,slightlydisruptedvirions,an\ntypesofviralparticlescontainingHAandNAaswellassplitvira\nshowed a highly heterogeneous mixture containing differen\nAdditional electron microscopy analysis of split vaccine cluster\nboth starfish- and peanut-shaped heterogeneous particles55\nsymmetrical and agglomerated into huge structures, resulting i\nstarfish-shaped;whereasinthesplitvaccinetheyaremostlynon\nrevealed that the HA rosette clusters in RIV4 are uniforml\nFurther characterisation by cryo-electron microscopy ha"
  },
  {
    "element_id": "elem_005_0040",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      37.065292053222656,
      366.37185058593747,
      282.0563525390625,
      503.10228515625
    ],
    "confidence": 0.9897176027297974,
    "reading_order": 3,
    "content": "xclusion high-performance liquid chromatography is monitore\nlution of rHA from RIV4 drug substance as a single peak in size\nlusteratanaveragediameterofapproximately30\u201340nm55,67.Th\nnd presentation, containing around six to eight HA trimers pe\n500nm)66.However,therosetteclustersinRIV4areuniforminsiz\nf 150nm, while the remainder are larger (average diamete\nlusterhavebeenobserved;themajorityhaveanaveragediamete\no 1100 trimers per cluster55,66,67. Two distinct populations o\nonventionalinfluenzavirus-derivedvaccines,withestimatesof1\nhey form clusters of varying sizes. This has been observed i\nrimer (rosette). When these are extracted from influenza viruse\ns described above, HA is expressed on the viral surface as a H"
  },
  {
    "element_id": "elem_005_0041",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      301.18840576171874,
      548.797060546875,
      550.1032470703125,
      735.3944384765625
    ],
    "confidence": 0.9924058318138123,
    "reading_order": 4,
    "content": "vaccine strains had led to loss of a glycosylation site and\ncell-grown vaccine reference virus, egg propagation of the\nthe circulating A/H3N2 viruses were antigenically similar to the\nthisstrain(p = 0.003).Theinvestigatorssuggestedthatalthough\nreceipt of RIV4 was strongly associated with seroconversion to\nH3N2weregenerallylowandsimilaracrossallgroups,however,\naIIV3. Post-vaccination titre against the antigenically drifted\ncirculating viruses was twice as high for RIV4 as for HD-IIV3 or\nThe post-vaccination geometric mean fold rise against the two\nanantigenicallyadvanced viruswithevidenceofantigenicdrift.\npropagated referencevaccinestrain, twocirculatingviruses and\nsera were tested against four A/H3N2 viruses including a cell-\nSanofi Pasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant\ninactivated trivalent influenza vaccine (Fluzone\u00ae High Dose,\n65\u201374 years were immunised with RIV4, a high-dose split-virion\nhumans. In a small study by Belongia et al.82, participants aged\nantibody responses to antigenically drifted A/H3N2 viruses in\nRIV4 has a unique ability to induce broadly cross-reactive"
  },
  {
    "element_id": "elem_005_0042",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      300.73743896484376,
      399.57552246093746,
      547.407421875,
      550.716064453125
    ],
    "confidence": 0.9970153570175171,
    "reading_order": 5,
    "content": "12,81\nvaccines and whether this underlies the cross-protection agains\nrHA elicits a broader antibody repertoire than convention\nPasteur)60.Thesedatawarrantadditionalstudiestoverifywhethe\n(Flucelvax\u00ae Tetra, Seqirus, and Fluzone\u00ae quadrivalent SD, Sano\ncompared to egg- or mammalian cell-derived split vaccine\nantibodyresponseagainstHA1havealsobeenobservedwithRIV\n[Trivalent])77. Higher magnitudes of haemagglutination inhibitor\ntraditional mammalian cell-derived subunit vaccine (Flucelvax\nepitopes in the HA head region, at greater proportions than\ninducesantibodies,inbothhumansandmice,thatarespecifict\nhumans,withthehighesttitresobservedintheelderly78.RIV4als\nH1, H3 and B haemagglutinin in an age-dependent manner i\nspecificneutralisingantibodiesdirectedagainstinfluenzasubtype\nIn a study by Nachbagauer et al.78, RIV4 induced HA stem"
  },
  {
    "element_id": "elem_005_0043",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      303.173349609375,
      236.40958740234373,
      548.0217773437499,
      401.0730029296875
    ],
    "confidence": 0.9957446455955505,
    "reading_order": 6,
    "content": "12,71,76\u201380\nonservedregionsofthemoleculefortheinductionofimmunit\nlycosylation in ensuring the proper folding of HA, and expose\nqually efficient to that of chicken or mammalian cell-derive\nlycans76\u201379. The presence of simpler glycans appears to b\nross-clade protection compared to HA with more comple\nlycans induce more broadly protective antibodies with superio\nrotection. Subsequent studies showed that HA with simple\nre not essential for HA structure may improve vaccine-induce\nully glycosylated HA75. Thus, elimination of parts of glycans tha\nethal challenge with H5N1 compared to antisera raised agains\nnd capacity of HA-neutralising antibodies to protect agains\nonoglycosylatedHAinmicewereshowntoimprovethebreadt\nould provide broader specificity. Antisera raised against simpl\nonservedand,assuch,antibodiesdirectedagainsttheseregion\nThe peptide sequences around glycosylation sites are highl"
  },
  {
    "element_id": "elem_005_0044",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      302.72625,
      84.34361206054687,
      549.2882373046875,
      240.71675537109374
    ],
    "confidence": 0.9911256432533264,
    "reading_order": 7,
    "content": "nsectcells had relativelysmallpaucimannose glycans (Fig. 2)72.\nomplex or high-mannose glycans, whereas HA expressed in Sf\nidney)cell-derivedHApredominantlycontainedhighly-branche\nhowed that egg-derived and mammalian (Madin-Darby canin\naucimannosidic or oligomannosidic glycans)74. An et al.7\nypically have simple unsialylated glycans (either truncated\nype N-linked glycans, while those expressed in insect cell\nxpressed in mammalian cells typically have sialylated complex\netermining HA N-glycan composition72,73. Glycoprotein\nhe host cells used for the production of HA play a major role i\nndaroleindiseasepathogenesis71.Duringvaccinemanufacture\nas various functions, including regulation of the virus life-cycl\negionandtheconservedstemregion71.TheglycosylationofH\ndependingonthevirusstrainandsubtype)intheglobularhea\nnfluenzaHAhasavariablenumberofN-linkedglycosylationsite"
  },
  {
    "element_id": "elem_005_0045",
    "page_num": 5,
    "element_type": "title",
    "bbox": [
      299.89037109375,
      56.7614794921875,
      545.5100830078125,
      87.03180725097656
    ],
    "confidence": 0.9655909538269043,
    "reading_order": 8,
    "content": "HAINOTHERINFLUENZA VACCINES\nPRODUCED ININSECT CELLS DIFFERS SIGNIFICANTLY FROM\nTHEN-LINKED GLYCAN STRUCTUREOFRECOMBINANT HA"
  },
  {
    "element_id": "elem_005_0046",
    "page_num": 5,
    "element_type": "title",
    "bbox": [
      35.81140869140625,
      335.4143115234375,
      283.49830810546877,
      365.23946777343747
    ],
    "confidence": 0.9188194274902344,
    "reading_order": 9,
    "content": "INFLUENZAVACCINES\nMAYIMPROVE THESAFETYPROFILE OVERCONVENTIONAL\nTHEHOMOGENEITYOFRECOMBINANTHAANTIGENSINRIV"
  },
  {
    "element_id": "elem_005_0047",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      36.17580322265625,
      97.22513671875,
      286.5204711914062,
      298.7607788085937
    ],
    "confidence": 0.9864022135734558,
    "reading_order": 10,
    "content": "fi 65\nmphasised the relevance of these features in determining\nontributedtotheobservedrobustimmuneresponseforRIV4and\nion of rHA and absence of other influenza viral proteins in RIV4\nheothertwovaccines.Authorspostulatedthatsimplerglycosyla-\nesponses,withsignificantlyhigherT-cellandantibodylevelsthan\n016\u20132017, and 2017\u20132018)65. RIV4 elicited the most robust\naccineorRIV4forthreesuccessiveinfluenzaseasons(2015\u20132016,\ndults who received egg-derived split vaccine, cell-derived split\nt al.65 examined CD4 T-cell and antibody responses in healthy\nomains than egg-derived split vaccines64. Recently Richards\ngainst highly conserved regions of the HA head and stem\nignificantly higher levels of broadly cross-reactive antibodies\northeH3strain)producedusingBEVS(asusedforRIV4),induced\nt al.64 demonstrated that recombinant HA antigens (specifically\nmmune response to vaccines in humans and animals. Portnoff\nesult in differences, both qualitative and quantitative, in the\netween recombinant and split vaccines have been shown to\nStructural differences in the HA polypeptides and rosettes"
  },
  {
    "element_id": "elem_005_0048",
    "page_num": 5,
    "element_type": "text",
    "bbox": [
      35.66513122558594,
      58.02353942871093,
      286.1814111328125,
      98.60310791015624
    ],
    "confidence": 0.9610600471496582,
    "reading_order": 11,
    "content": "epitopes in the pre-fusion HA0 molecules, which are present in\nand post-fusion states, and the presence of unique neutralising\nclearlydemonstrate structural differences betweenHApre-fusion"
  },
  {
    "element_id": "elem_006_0049",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      43.785129089355465,
      715.657060546875,
      294.8968212890625,
      735.8655322265624
    ],
    "confidence": 0.9649184346199036,
    "reading_order": 1,
    "content": "the BEVS used in the manufacture of RIV4 over conventional\nThe evidence reviewed here demonstrates several advantages of"
  },
  {
    "element_id": "elem_006_0050",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      45.863709411621095,
      594.3571435546875,
      294.6070239257812,
      684.7966845703124
    ],
    "confidence": 0.9977753758430481,
    "reading_order": 2,
    "content": "ulnerable individuals93.\ndverse reactions, although rare, to these components in\nional vaccines are absent in RIV4 would eliminate potential\ngents or hydrocortisone that are typically present in conven-\nrotein, viral RNA, and process impurities such as inactivating\nlinical manifestations of allergic disease upon exposure92. Egg\nvalbuminandthosewhoaresensitisedmaybeathigherriskof\nisk of hypersensitivity reactions to component proteinssuchas\nAlthough uncommon, some individuals may be at increased"
  },
  {
    "element_id": "elem_006_0051",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      45.05977111816406,
      465.62910644531246,
      293.1829541015625,
      596.8121044921875
    ],
    "confidence": 0.9941898584365845,
    "reading_order": 3,
    "content": "arenot present inrecombinant vaccines.\nproteins (as described above) and influenza viral RNA fragment\nassay)90,91. Such egg-derived or other influenza virus-derive\neffectiveness, and viral RNA fragments (confirmed by activit\ngraphicseparation)thatarenotshowntoberelevantforvaccin\nnucleoprotein and matrix protein (confirmed by a chromato\nvaccine preparations detected other viral proteins such a\n350ng/mL89. Moreover, another study of commercial influenz\nturers showed that the median ovalbumin concentration wa\nseasonal influenza vaccines produced by five different manufac\negg proteins. Testing of 58 vaccine lots covering six differen\nvirusesthataregrowninembryonatedchickeneggs,theycontai\nAs most split and subunit vaccines are prepared from in uenz"
  },
  {
    "element_id": "elem_006_0052",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      45.71754180908203,
      433.43995605468746,
      293.377236328125,
      463.6290673828125
    ],
    "confidence": 0.9584028720855713,
    "reading_order": 4,
    "content": "NRECOMBINANT HA VACCINE ISLIKELY TO FAVOUR ITS\nBSENCEOFEGGOROTHERINFLUENZAVIRALCOMPONENTS"
  },
  {
    "element_id": "elem_006_0053",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      44.721430664062495,
      702.6099169921874,
      104.87681762695313,
      713.634169921875
    ],
    "confidence": 0.9971299767494202,
    "reading_order": 5,
    "content": "CONCLUSIONS"
  },
  {
    "element_id": "elem_006_0054",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      314.8402368164062,
      715.3577490234375,
      559.8282568359375,
      733.2585205078125
    ],
    "confidence": 0.6996215581893921,
    "reading_order": 6,
    "content": "matchedstrains:asystematicreviewandmeta-analysis. BMCMed. 11,153(2013).\n7. Tricco,A.C.etal.Comparingin uenzavaccineef cacyagainstmismatchedand"
  },
  {
    "element_id": "elem_006_0055",
    "page_num": 6,
    "element_type": "list",
    "bbox": [
      306.43701416015625,
      354.14123291015625,
      561.704677734375,
      726.760810546875
    ],
    "confidence": 0.9892112016677856,
    "reading_order": 7,
    "content": "17. Tricco,A.C.etal.Comparinginfluenzavaccineefficacyagainstmismatchedand\n4099\u20134103(2009).\nvaccineagainstBvirusesoftheB/VictoriaorB/Yamagatalineages. Vaccine 27,\nagedandelderlyvolunteersafterMF59-adjuvantedsubunittrivalentinfluenza\n16. Camilloni,B.,Neri,M.,Lepri,E.&Iorio,A.M.Cross-reactiveantibodiesinmiddle-\nsed17February2021.(2021).\n(GISRS). Available at https://www.who.int/influenza/gisrs_laboratory/en/. Acces-\n15. WorldHealthOrganization.GlobalInfluenzaSurveillanceandResponseSystem\ncine. Vaccines 8,409(2020).\nneuraminidase:aneglectedproteinanditspotentialforabetterinfluenzavac-\n14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza\n2465\u20132494(2014).\nin influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6,\n13. Wohlbold,T.J.&Krammer,F.Intheshadowofhemagglutinin:agrowinginterest\nageorolder. N.Engl.J.Med. 376,2427\u20132436(2017).\n12. Dunkle,L.M.etal.Efficacyofrecombinantinfluenzavaccineinadults50yearsof\nrelateofvaccine-inducedprotection. J.Infect.Dis. 204,1879\u20131885(2011).\n11. Ohmit,S.E.etal.Influenzahemagglutination-inhibitionantibodytiterasacor-\nwithinfluenzaA2andBviruses. Epidemiol.Infect. 70,767\u2013777(1972).\nhaemagglutination-inhibitingantibodyinprotectionagainstchallengeinfection\n10. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum\n9. Paules,C.&Subbarao,K.Influenza. Lancet 390,697\u2013708(2017).\n8. Krammer,F.etal.Influenza. Nat.Rev.Dis.Prim. 4,3(2018).\nSupplB,11\u201315(1999).\n7. Szucs,T.Thesocio-economicburdenofinfluenza. J.Antimicrob.Chemother. 44\nincomecountries. Vaccine 33,6537\u20136544(2015).\nreview of the social and economic burden of influenza in low- and middle-\n6. deFranciscoShapovalova,N.,Donadel,M.,Jit,M.&Hutubessy,R.Asystematic\nInfluenzaOtherRespir.Viruses 11,372\u2013393(2017).\ninfluenza:areviewoftheextra-pulmonarycomplicationsofinfluenzainfection.\n5. Sellers,S.A.,Hagan,R.S.,Hayden,F.G.&Fischer,W.A.IIThehiddenburdenof\nMarch2021.\nSurveillance Report. https://www.cdc.gov/flu/weekly/index.htm. Accessed 16\n4. US Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza\nanalysis. PLoSMed. 18,e1003550(2021).\ninfections and hospitalizations among adults: a systematic review and meta-\n3. Lafond,K.E.etal.Globalburdenofinfluenza-associatedlowerrespiratorytract\nMarch2021.(2018).\nwww.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).Accessed12\n2. WorldHealthOrganization.Fact-sheet.Influenza(Seasonal).Availableathttps://\nmortality:amodellingstudy. Lancet 391,1285\u20131300(2018)."
  },
  {
    "element_id": "elem_006_0056",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      311.44350585937497,
      335.59995849609373,
      361.82335693359374,
      345.64928466796874
    ],
    "confidence": 0.978653073310852,
    "reading_order": 8,
    "content": "EFERENCES"
  },
  {
    "element_id": "elem_006_0057",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      312.0809545898437,
      287.3136840820312,
      517.2846240234375,
      308.33549560546874
    ],
    "confidence": 0.9295899868011475,
    "reading_order": 9,
    "content": "eceived:24May2021; Accepted: 3November 2021"
  },
  {
    "element_id": "elem_006_0058",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      309.91581298828123,
      266.90934814453124,
      447.21382324218746,
      276.29369384765624
    ],
    "confidence": 0.9608618021011353,
    "reading_order": 10,
    "content": "Nodataweregeneratedforthereviewarticl"
  },
  {
    "element_id": "elem_006_0059",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      311.7868505859375,
      254.60624267578123,
      392.5760888671875,
      265.2382177734375
    ],
    "confidence": 0.9969758987426758,
    "reading_order": 11,
    "content": "ATAAVAILABILITY"
  },
  {
    "element_id": "elem_006_0060",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      310.41509765625,
      58.06283203125,
      560.1719970703125,
      236.82287109375
    ],
    "confidence": 0.9835387468338013,
    "reading_order": 12,
    "content": "aspandemicinfluenzaand/orCOVID-19.\ncross-protectionagainstconstantlyevolvingvariantsiscritical,such\nbeextended to addressotheremerging infectious diseaseswhere\nestablished and validated platform for vaccine manufacture could\nimpurities in vulnerable individuals are eliminated. This well-\negg-protein, and thus potential adverse reactions to these\nrelated process-impurities such as inactivating agents or residual\nthe need for a viral inactivation step and avoids the use of eggs,\nimpurities are the hallmarks of RIV4. As rHA production bypasses\nhomogeneity of rHA rosettes and negligible process-related\ntogether with the direct or indirect evidence supporting this. The\nforthegenerationofbroadcross-reactiveandprotectiveantibodies,\nfeaturesoftherHAtertiarystructurethatarelikelytoberesponsible\nHA structure through egg- or cell-adaptation. We also describe\ntheriskofantigenicmismatchduetopotentialchangesinprimary\nenrichment.Theuseofrecombinantproteintechnologyeliminates\normammaliancells,splitwithdetergentswithorwithoutfurtherHA\nin uenzavaccinesthatrelyonin uenzavirionspropagatedinegg"
  },
  {
    "element_id": "elem_006_0061",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      45.538530578613276,
      316.020234375,
      294.84613037109375,
      415.54604003906246
    ],
    "confidence": 0.9683619737625122,
    "reading_order": 13,
    "content": "reserving the native HA conformation of the wild-type virus,\nines, RIV4 does not go through an inactivation step, thus\nolding, conformation, and stability88. Unlike conventional vac-\nroups85\u201387.Thesemodificationsoftenresultinchangestoprotein\npitopesonHAthroughcross-linkingorformationofbis-alkylated\nnactivatingagentscausenumerousmodificationstotheantigenic\ngents such as formaldehyde or \u03b2-propiolactone (BPL). These\nr mammalian cells, the antigens are exposed to inactivation\nnallconventionalin uenzavaccines,whetherderivedfromeggs"
  },
  {
    "element_id": "elem_006_0062",
    "page_num": 6,
    "element_type": "title",
    "bbox": [
      46.4923828125,
      294.08561279296873,
      272.50925537109373,
      315.16677246093747
    ],
    "confidence": 0.9940453767776489,
    "reading_order": 14,
    "content": "HEMICALMODIFICATIONS\nECOMBINANTHA ANTIGENSARENOT SUBJECTED TO"
  },
  {
    "element_id": "elem_006_0063",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      45.55305725097656,
      73.37817993164062,
      294.63662109374997,
      276.20299072265624
    ],
    "confidence": 0.9614008665084839,
    "reading_order": 15,
    "content": "fl\nanprotectagainstdriftedvirusesandthusmayconferagreater\naccine constructs that preserve the highly conserved HA stem\n3N2 virus strains evaluated by Belongia et al.82. Therefore,\nxposuretodivergentinfluenzavirusessimilartothemultipleA/\nith age78. This increase with age is possibly due to repeated\neactive antibodies and that these immune responses increase\naccineresultsinincreasedtitreofbroadlyneutralisingHAstem-\naeur et al.78 supports the hypothesis that a recombinant\ngainstmismatchedinfluenzastrains12,75.Thestudy by Nachba-\nn smaller N-linked glycans) may contribute to cross-protection\nonservedstemregionofrHAproducedininsectcells(resulting\nhe higher quantity and greater accessibility of the genetically\noglycosylationofrHAintheinsectcellline,leavingituncleaved.\nniquecharacteristicoftherecombinantvaccineislikelyrelated\niskforinfluenzaandassociatedmedicalcomplications83,84.This\n/H3N2 strains, including in older adults who are at a higher\nrotective responses against both circulating and drifted\ny Shinde et al.83 baculovirus-expressed rHA generated cross-\nInadditionto the above referenced studies,ina recent study"
  },
  {
    "element_id": "elem_006_0064",
    "page_num": 6,
    "element_type": "text",
    "bbox": [
      43.47267242431641,
      58.48276245117187,
      291.59402343749997,
      77.26831237792969
    ],
    "confidence": 0.7472254037857056,
    "reading_order": 16,
    "content": "with previous reports26."
  },
  {
    "element_id": "elem_007_0065",
    "page_num": 7,
    "element_type": "list",
    "bbox": [
      33.785266113281246,
      63.77546447753906,
      553.8532763671875,
      730.83779296875
    ],
    "confidence": 0.8955439925193787,
    "reading_order": 1,
    "content": "controlledtrialofadultsinMexico. Vaccine 29,7826\u20137834(2011). 10.1128/JVI.01693-18(2019).\ndemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneprocessing. JVirol.https://doi.org/\n44. L\u00f3pez-Mac\u00edas,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins:\nInfluenza-Vaccinology-Report.pdf.AccessedAugust2021. glycansinviralevolutionandvaccinedesign. Sci.Transl.Med. 2,24ra21(2010).\nobamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleof\nenterprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel. J.Med.Virol. 72,138\u2013142(2004).\n43. Report to the president on reengeneering the influenza vaccine production 70. Babiuk,S.etal.AggregatecontentinfluencestheTh1/Th2immuneresponseto\n27,33(2020). (2002).\n42. Chen,J.R.etal.Betterinfluenzavaccines:anindustryperspective. J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189\u2013196\nHum.VaccinImmunother. 11,1209\u20131222(2015). 69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultsof\n41. Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsinCanada. Can.Commun.Dis.Rep. 31,217\u2013225(2005).\nopingthenextgenerationofinfluenzavaccines. Vaccines 8,574(2020). vaccination:reviewofpost-marketing surveillance throughfourinfluenza sea-\n40. Sayedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel- 68. PublicHealthAgencyofCanada.Oculo-respiratorysyndromefollowinginfluenza\nvaccine. PLoSONE 7,e33428\u2013e33428(2012). 10.3390/vaccines6020031(2018).\nnogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza virus and within vaccines using electron microscopy. Vaccines https://doi.org/\n39. Pandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenza\n8028\u20138038(2018). tionofinfluenzavirusvaccine. Hum.VaccinesImmunother. 11,1673\u20131684(2015).\nderived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza-\n38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans. NPJVaccines 5,77(2020).\n1491\u20131503(2020). unit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-\nadults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards,K.A.etal.RecombinantHA-basedvaccineoutperformssplitandsub-\nrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).\n37. Ward,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad- neutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA. Vaccines\n18to49and>/=50yearsoldadults. PLoSONE 14,e0216533(2019). 64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly\nlikeparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions. Sci.Adv. 6,eaaz8822(2020).\n36. Pillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the\nImmunol. 168,72\u201387(2016). allinfluenzaAsubtypes. Cell 166,596\u2013608(2016).\ninduces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing\n35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope. Science 324,246\u2013251(2009).\nfightagainstCOVID-19? Vaccines 8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus\n34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans. Nat.Commun. 10,3338(2019).\nexpressedin Escherichiacoli. Gene 21,273\u2013284(1983). 60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross\n33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).\nbacteria. ActaBiochimPol. 61,561\u2013572(2014). separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,\n32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduces\nproducedin Escherichiacoli. PLoSONE 5,e11694(2010). (2015).\n31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323\u2013341\nproteins. OpenForumInfect.Dis. 3,ofw015(2016). 58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby\nseasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeofH3influenzavirusatacidicpH. Virology 126,587\u2013599\nONE 3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe\nbacterial expression: a solution to global pandemic and seasonal needs. PLoS insectandmammaliancells. Curr.Opin.Biotechnol. 10,428\u2013433(1999).\n29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor\n1560-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms. Clin.Vaccin.Immunol. 23,483\u2013495(2016).\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron microscopy and image analyses\nvisiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis- 55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccine\n28. Shu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from perspective. AnnuRev.Biophys. 47,153\u2013173(2018).\n167\u2013171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical\neffectiveness-UnitedStates,February2017. MMWRMorb.Mortal.WklyRep. 66, 406\u2013430(2015).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,\nNatlAcad.Sci.USA 114,12578\u201312583(2017). 53. Luczo,J.M.etal.MolecularpathogenesisofH5highlypathogenicavianinflu-\nthataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains. Proc. 95,409\u2013417(1998).\n26. Zost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginofthelabileconformation. Cell\ncirculatingviruses. PLoSONE 9,e92153(2014). 52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-\nwith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.\n25. Skowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprotease. EMBOJ. 11,2407\u20132414\negg-adaptedvaccinestrain. Nat.Med. 22,1465\u20131469(2016). 51. Stieneke-Gr\u00f6ber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage\n24. Raymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter. Proc.NatlAcad.Sci.USA 95,9713\u20139715(1998).\ncells. J.Invertebr.Pathol. 107,S31\u2013S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin cleavageintoHA1,HA2:no\n23. Cox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.\n10,702\u2013714(2015). drug-products/applications-submissions/register-innovative-drugs.html. Acces-\nmanufacturingplatformforviralvaccinesandgenetherapyvectors. Biotechnol.J. from https://www.canada.ca/en/health-canada/services/drugs-health-products/\n22. Felberbaum, R. S. The baculovirus expression vector system: a commercial 49. HealthCanada.RegisterofInnovativeDrugs[Updated15April2021].Available\nMed. 121,S22\u2013S27(2008). February2021.\nduction,distribution,supply,anddemand\u2013whatitmeansfortheprovider. Am.J. assessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17\n21. Orenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/\nplacebo-controlledphaseItrial. Nat.Med. 27,106\u2013114(2021). 48. European Medicines Agency. Assessment report. Supemtek. Procedure No.\nvaccine approach induces broad and long-lasting immunity in a randomized, 2021.\n20. Nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August\nvaccine:differentapproachesforonegoal. Virol.J. 15,17(2018). 47. Influenza vaccine strategies for broad global access. Available at https://path.\n19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles. ExpertRev.Vaccines 12,225\u2013236(2013).\n(2018). 46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like\ndefinedbyavaccine-inducedantibody. Proc.NatlAcad.Sci.USA 115,168\u2013173 ticlevaccine. Biopharm.Int 23Suppl10,26\u201334(2010)."
  },
  {
    "element_id": "elem_008_0066",
    "page_num": 8,
    "element_type": "list",
    "bbox": [
      43.23636474609375,
      51.78988037109375,
      290.74792236328125,
      553.52126953125
    ],
    "confidence": 0.9650207757949829,
    "reading_order": 1,
    "content": "Chromatogr.A 1123,225\u2013232(2006).\nnon-porousreversed-phasehighperformanceliquidchromatographycolumns.\ninfluenzavirusconstituentsinmonovalentandmultivalentpreparationsusin\n91. Garcia-Canas,V.,Lorbetskie,B.&Girard,M.Rapidandselectivecharacterization\nchromatographyand fluorescencedetection. Anal.Chem. 79,3164\u20133172(2007\nproteinsincommercialvaccinesusingtwo-dimensionalhigh-performanceliqui\n90. Garcia-Canas, V. et al. Selective and quantitative detection of influenza viru\nvaccines. J.AllergyClin.Immunol. 125,1412\u20131413(2010).authorreply1413-141\n89. Li,J.T.,Rank,M.A.,Squillace,D.L.&Kita,H.Ovalbumincontentofinfluenz\n1630\u20131637(2019).\ninactivationmethodsoninfluenzavirionstooptimize. Vaccin.Prod.Vaccin. 3\n88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect\ntionby \u03b2-propiolactone. Proteomics 13,3537\u20133547(2013).\n87. She,Y.M.etal.Surfacemodificationsofinfluenzaproteinsuponvirusinactiv\ntionsfortheinactivationofviruses. J.Biol.Chem. 286,36198\u201336214(2011).\npropiolactone with nucleobase analogues, nucleosides, and peptides: implic\n86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of bet\ntination,hemagglutination,andantigenicity. Appl.Microbiol. 19,290\u2013294(1970\nthiolate,andultravioletlightuponinfluenzavirusinfectivitychickencellaggl\n85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, me\n59,1057\u20131062(2010).\nseasonalinfluenza \u2014 UnitedStates,1976-2007. MMWRMorb.Mortal.WklyRe\n84. Centers for Disease Control Prevention. Estimates of deaths associated wit\nhttps://doi.org/10.1093/cid/ciaa1673(2020).\nadjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Di\nand polyfunctional CD4+ T-cell responses by a recombinant matrix-\n83. Shinde,V.etal.Inductionofcross-reactivehemagglutinationinhibitingantibod\ninadults65to74years,2017-2018. Vaccine 38,3121\u20133128(2020).\nvanted,andrecombinantinfluenzavaccinesagainstcell-grownA(H3N2)viruse\n82. Belongia,E.A.etal.Clinicaltrialtoassessimmunogenicityofhigh-dose,adj\nplacebo-controlledtrial. Vaccine 29,7733\u20137739(2011).\nproteinvaccine (FluBlok(R)) against influenzain healthyadults:a randomize\n81. Treanor,J.J.etal.Protectiveefficacyofatrivalentrecombinanthemagglutini\n2176\u20132185(2006).\nstep closer to a recombinant protein-based influenza vaccine. Vaccine 2\n80. Wang,K.etal.Expressionandpurificationofaninfluenzahemagglutinin\u2013on\nBMCInfect.Dis. 10,5(2010).\nthecaseagedistributionandunusualtoxicityinpandemicnovelH1N1influenza\n79. Reichert,T.etal.Doesglycosylationasamodifieroforiginalantigenicsinexplai\nhemagglutininstalk-reactiveantibodiesinhumans. mBio 7,e01996\u201301915(2016\n78. Nachbagauer,R.etal.Agedependenceandisotypespecificityofinfluenzaviru\nVirol. https://doi.org/10.1128/JVI.01150-19(2019).\nvaccineversussubunitinactivatedinfluenzavirusvaccine:acomparativestudy.\n77. Henry,C.etal.Monoclonalantibodyresponsesafterrecombinanthemagglutini\n2476\u20132481(2014).\nstrainprotectionagainstinfluenzavirusinfections. Proc.NatlAcad.Sci.USA 11\n76. Chen,J.R.etal.Vaccinationofmonoglycosylatedhemagglutinininducescros\nimmuneresponse. Proc.NatlAcad.Sci.USA 106,18137\u201318142(2009).\n75. Wang,C.C.etal.Glycansoninfluenzahemagglutininaffectreceptorbindingan\ndoms. Cell 171,258\u2013258.e251(2017).\n74. Chung,C.Y.etal.SnapShot:N-glycosylationprocessingpathwaysacrosskin\nviralhemagglutinin. Vaccine 27,4325\u20134336(2009).\nduction:influenceofhostcelllineandvirusstrainontheglycosylationpattern\n73. Schwarzer,J.etal.Glycananalysisincellculture-basedinfluenzavaccinepr"
  },
  {
    "element_id": "elem_008_0067",
    "page_num": 8,
    "element_type": "title",
    "bbox": [
      311.48962646484375,
      536.7035302734375,
      374.589580078125,
      546.1002685546874
    ],
    "confidence": 0.5391474366188049,
    "reading_order": 2,
    "content": "TheAuthor(s)202"
  },
  {
    "element_id": "elem_008_0068",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      312.8496459960937,
      425.94319335937496,
      559.4053271484374,
      515.6194921875
    ],
    "confidence": 0.9889256358146667,
    "reading_order": 3,
    "content": "romthecopyrightholder.Toviewacopyofthislicense,visithttp://creativecommons.\negulationorexceedsthepermitteduse,youwillneedtoobtainpermissiondirectly\nrticle\u2019sCreativeCommonslicenseandyourintendeduseisnotpermittedbystatutor\nndicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthe\naterialinthisarticleareincludedinthearticle\u2019sCreativeCommonslicense,unless\nommonslicense,andindicateifchangesweremade.Theimagesorotherthirdparty\nppropriatecredittotheoriginalauthor(s)andthesource,providealinktotheCreative\ndaptation,distributionandreproductioninanymediumorformat,aslongasyougive\nAttribution 4.0 International License, which permits use, sharing,"
  },
  {
    "element_id": "elem_008_0069",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      311.91277587890625,
      377.5162060546875,
      560.95435546875,
      393.761689453125
    ],
    "confidence": 0.9508141279220581,
    "reading_order": 4,
    "content": "npublishedmapsandinstitutionalaffiliations.\nublishersnote SpringerNatureremainsneutralwithregardtojurisdictionalclaims"
  },
  {
    "element_id": "elem_008_0070",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      310.23169189453125,
      350.49781494140626,
      559.8204345703125,
      368.11878662109376
    ],
    "confidence": 0.7079799771308899,
    "reading_order": 5,
    "content": "reprints\nReprints and permission information is available at http://www.nature.com/"
  },
  {
    "element_id": "elem_008_0071",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      309.8444677734375,
      323.2904150390625,
      563.9789355468749,
      341.01635009765624
    ],
    "confidence": 0.9698144793510437,
    "reading_order": 6,
    "content": "Arunachalam.\nCorrespondence and requests for materials should be addressed to Arun B."
  },
  {
    "element_id": "elem_008_0072",
    "page_num": 8,
    "element_type": "title",
    "bbox": [
      310.2955224609375,
      310.4438818359375,
      426.0488818359375,
      321.2746435546875
    ],
    "confidence": 0.9886133670806885,
    "reading_order": 7,
    "content": "ADDITIONAL INFORMATION"
  },
  {
    "element_id": "elem_008_0073",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      311.0895263671875,
      274.89796875,
      557.7861181640625,
      292.10737060546876
    ],
    "confidence": 0.9914585947990417,
    "reading_order": 8,
    "content": "optionsinthecompany.\nAll authors are employees of Sano Pasteur and may hold shares and/or stoc"
  },
  {
    "element_id": "elem_008_0074",
    "page_num": 8,
    "element_type": "title",
    "bbox": [
      310.2853051757812,
      261.522861328125,
      407.6010791015625,
      272.5695703125
    ],
    "confidence": 0.9792298674583435,
    "reading_order": 9,
    "content": "COMPETINGINTERESTS"
  },
  {
    "element_id": "elem_008_0075",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      311.89025390625,
      209.026669921875,
      558.2255712890625,
      244.46414794921873
    ],
    "confidence": 0.9942757487297058,
    "reading_order": 10,
    "content": "ccountablefortheaccuracyandintegrityofthework.\nndcommentedonthemanuscriptatallstages,approvedthe finaldraft,andremai\nxpandedtheclinicalandtheregulatorysectionsrespectively;allauthorsreviewe\n.A.conceptualised,designed,andpreparedtheoriginaldraftandFig.2;D.R.andP."
  },
  {
    "element_id": "elem_008_0076",
    "page_num": 8,
    "element_type": "title",
    "bbox": [
      310.1530517578125,
      195.25493408203124,
      416.3020751953125,
      206.31254150390623
    ],
    "confidence": 0.9977368116378784,
    "reading_order": 11,
    "content": "AUTHORCONTRIBUTIONS"
  },
  {
    "element_id": "elem_008_0077",
    "page_num": 8,
    "element_type": "text",
    "bbox": [
      312.4850537109375,
      134.10763549804688,
      558.5466796874999,
      177.60253051757812
    ],
    "confidence": 0.9962131977081299,
    "reading_order": 12,
    "content": "anuscriptcoordination.\nheauthorsalsothankKathrynBonaparte(Sanofi Pasteur)foreditorialassistancean\nanofi Pasteur. Graphic design support provided by Naveen Kandibanda (Sanofi)\nray,inScienceCommunications,SpringerHealthcareLtd,UKandwasfundedb\nditorialassistancewiththepreparationofthemanuscriptwasprovidedbyJuliett"
  },
  {
    "element_id": "elem_008_0078",
    "page_num": 8,
    "element_type": "title",
    "bbox": [
      311.18690917968746,
      121.07965209960938,
      403.5185595703125,
      131.647939453125
    ],
    "confidence": 0.993751585483551,
    "reading_order": 13,
    "content": "ACKNOWLEDGEMENTS"
  },
  {
    "element_id": "elem_008_0079",
    "page_num": 8,
    "element_type": "list",
    "bbox": [
      309.44729003906247,
      59.36978759765625,
      560.5887744140625,
      104.46802734375
    ],
    "confidence": 0.737604558467865,
    "reading_order": 14,
    "content": "2021.\npinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed August\n93. Vaccineexcipientsummary.Availableathttps://www.cdc.gov/vaccines/pubs/\ndiseasesinchildren. J.Microbiol.Immunol.Infect. 49,112\u2013118(2016).\n92. Lin,Y.T.etal.Correlationofovalbuminofeggwhitecomponentswithallergic"
  }
]